Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Oct;74(4):343–347. doi: 10.1136/hrt.74.4.343

Angiographic trials of lipid-lowering therapy: end of an era?

G R Thompson 1
PMCID: PMC484035  PMID: 7488443

Full text

PDF
343

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blankenhorn D. H., Azen S. P., Kramsch D. M., Mack W. J., Cashin-Hemphill L., Hodis H. N., DeBoer L. W., Mahrer P. R., Masteller M. J., Vailas L. I. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993 Nov 15;119(10):969–976. doi: 10.7326/0003-4819-119-10-199311150-00002. [DOI] [PubMed] [Google Scholar]
  2. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  3. Brensike J. F., Levy R. I., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W., Moriarty D. J. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):313–324. doi: 10.1161/01.cir.69.2.313. [DOI] [PubMed] [Google Scholar]
  4. Brown B. G., Zhao X. Q., Sacco D. E., Albers J. J. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med. 1993;44:365–376. doi: 10.1146/annurev.me.44.020193.002053. [DOI] [PubMed] [Google Scholar]
  5. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
  6. Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A., Smink R. D., Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med. 1990 Oct 4;323(14):946–955. doi: 10.1056/NEJM199010043231404. [DOI] [PubMed] [Google Scholar]
  7. Cashin-Hemphill L., Mack W. J., Pogoda J. M., Sanmarco M. E., Azen S. P., Blankenhorn D. H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990 Dec 19;264(23):3013–3017. [PubMed] [Google Scholar]
  8. Davies M. J., Krikler D. M., Katz D. Atherosclerosis: inhibition of regression as therapeutic possibilities. Br Heart J. 1991 Jun;65(6):302–310. doi: 10.1136/hrt.65.6.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haskell W. L., Alderman E. L., Fair J. M., Maron D. J., Mackey S. F., Superko H. R., Williams P. T., Johnstone I. M., Champagne M. A., Krauss R. M. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994 Mar;89(3):975–990. doi: 10.1161/01.cir.89.3.975. [DOI] [PubMed] [Google Scholar]
  10. Hodis H. N., Mack W. J., Azen S. P., Alaupovic P., Pogoda J. M., LaBree L., Hemphill L. C., Kramsch D. M., Blankenhorn D. H. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994 Jul;90(1):42–49. doi: 10.1161/01.cir.90.1.42. [DOI] [PubMed] [Google Scholar]
  11. Kane J. P., Malloy M. J., Ports T. A., Phillips N. R., Diehl J. C., Havel R. J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed] [Google Scholar]
  12. Kehely A., MacMahon M., Barbir M., Wray R., Hunt B. J., Prescott R. J., Thompson G. R. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. QJM. 1995 Jun;88(6):421–427. [PubMed] [Google Scholar]
  13. Krauss R. M., Lindgren F. T., Williams P. T., Kelsey S. F., Brensike J., Vranizan K., Detre K. M., Levy R. I. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987 Jul 11;2(8550):62–66. doi: 10.1016/s0140-6736(87)92734-6. [DOI] [PubMed] [Google Scholar]
  14. Levy R. I., Brensike J. F., Epstein S. E., Kelsey S. F., Passamani E. R., Richardson J. M., Loh I. K., Stone N. J., Aldrich R. F., Battaglini J. W. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation. 1984 Feb;69(2):325–337. doi: 10.1161/01.cir.69.2.325. [DOI] [PubMed] [Google Scholar]
  15. Marburger C., Hambrecht R., Niebauer J., Schoeppenthau M., Scheffler E., Hauer K., Schuler G., Schlierf G. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol. 1994 Apr 15;73(11):742–746. doi: 10.1016/0002-9149(94)90874-5. [DOI] [PubMed] [Google Scholar]
  16. Ornish D., Brown S. E., Scherwitz L. W., Billings J. H., Armstrong W. T., Ports T. A., McLanahan S. M., Kirkeeide R. L., Brand R. J., Gould K. L. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990 Jul 21;336(8708):129–133. doi: 10.1016/0140-6736(90)91656-u. [DOI] [PubMed] [Google Scholar]
  17. Sacks F. M., Pasternak R. C., Gibson C. M., Rosner B., Stone P. H. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994 Oct 29;344(8931):1182–1186. doi: 10.1016/s0140-6736(94)90506-1. [DOI] [PubMed] [Google Scholar]
  18. Schuler G., Hambrecht R., Schlierf G., Niebauer J., Hauer K., Neumann J., Hoberg E., Drinkmann A., Bacher F., Grunze M. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992 Jul;86(1):1–11. doi: 10.1161/01.cir.86.1.1. [DOI] [PubMed] [Google Scholar]
  19. Stewart B. F., Brown B. G., Zhao X. Q., Hillger L. A., Sniderman A. D., Dowdy A., Fisher L. D., Albers J. J. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994 Mar 15;23(4):899–906. doi: 10.1016/0735-1097(94)90635-1. [DOI] [PubMed] [Google Scholar]
  20. Thompson G. R., Maher V. M., Matthews S., Kitano Y., Neuwirth C., Shortt M. B., Davies G., Rees A., Mir A., Prescott R. J. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995 Apr 1;345(8953):811–816. doi: 10.1016/s0140-6736(95)92961-4. [DOI] [PubMed] [Google Scholar]
  21. Watts G. F., Lewis B., Brunt J. N., Lewis E. S., Coltart D. J., Smith L. D., Mann J. I., Swan A. V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992 Mar 7;339(8793):563–569. doi: 10.1016/0140-6736(92)90863-x. [DOI] [PubMed] [Google Scholar]
  22. Watts G. F., Mandalia S., Brunt J. N., Slavin B. M., Coltart D. J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993 Nov;42(11):1461–1467. doi: 10.1016/0026-0495(93)90199-x. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES